Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
06:21pm, Thursday, 01'st Aug 2024
Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.25 per share a year ago.
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
04:05pm, Thursday, 01'st Aug 2024
Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:07am, Thursday, 25'th Jul 2024
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
01:04pm, Monday, 22'nd Jul 2024
Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS).
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 19'th Jul 2024
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
10:06am, Thursday, 18'th Jul 2024
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 20'th Jun 2024
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
03:27pm, Monday, 17'th Jun 2024
Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
08:49pm, Thursday, 13'th Jun 2024
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
11:18am, Thursday, 13'th Jun 2024
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
06:16am, Thursday, 13'th Jun 2024
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:05pm, Wednesday, 12'th Jun 2024
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
04:00pm, Wednesday, 12'th Jun 2024
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval
Ultragenyx (RARE) Posts New Data From Bone Disease Study
11:50am, Wednesday, 12'th Jun 2024
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014)
